Athersys Company Profile
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
As represented by its name, (Athersys - derived from advanced therapeutic systems), the Company is committed to developing novel therapeutic products that deliver substantial improvements over existing therapies through the application and utilization of its advanced, proprietary technology platforms.
Through internal development and acquisition of key technologies, Athersys has established a unique blend of competencies in areas such as molecular biology, cell biology, genomics, protein biochemistry, medicinal chemistry, and pharmacology. The Company has fully integrated pre-clinical drug discovery and development capabilities, and is focused on advancing a portfolio of therapeutic development programs into the clinic.
3201 Carnegie Avenue
United States of America
Email: firstname.lastname@example.org., email@example.com
ByLouis Dematteis:Since early December, Athersys, Inc. (ATHX) is up more than 100%, with the company doubling in value from a little over $120M to its current capitalization of $240M. In an effort to...
By JDT Investments:Athersys (ATHX) is a clinical stage biotech company focused primarily on its proprietary "Off-the-Shelf" stem cell product called Multistem. In a previous article I took a comprehen...
NEW YORK CITY (dpa-AFX) - Athersys Inc. (ATHX) Thursday said Pfizer Inc.(PFE) has completed patient enrollment of a Phase II study that involves the administration of Athersys' MultiStem cell ther...
By U.S. Biotech Investor: Financial Biotechnology investors may want to take a look at Athersys, Inc. (ATHX) a quiet leader in the regenerative medicine field with a meager $308 million market cap....
Athersys Inc. (uses regenerative medicine to treat various conditions) netted $19.1mm through the sale of 5mm common shares at $4.10 each (a 38% premium) to returning shareholders. The company also is...
NEW YORK, Dec 17 (Reuters) - Athersys Inc : * Up 13.5 percent to $2.31 in premarket; says stem cell therapy gets orphan drug designation in Europe for prevention of graft-versus-host disease
Athersys Inc. (NASDAQ:ATHX) raised $20.5 million through the sale of 5 million units at $4.10 in a registered direct offering to institutional investors. Each unit comprises a share and a warrant to p...
ByBioStocksElite:Last week Athersys (ATHX) announced their quarterly earnings. As a shareholder, I find it important to listen to the quarterly conference calls because it gives shareholders insight a...
Drugs and Medications
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.As represented by its name, (Ather...
Athersys is a biotechnology company engaged in the research and development of products for the treatment and diagnosis of genetic and immunologic disorders. The company has a core expertise in the f...
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company...
More Information about "Athersys" on BioPortfolio
We have published hundreds of Athersys news stories on BioPortfolio along with dozens of Athersys Clinical Trials and PubMed Articles about Athersys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athersys Companies in our database. You can also find out about relevant Athersys Drugs and Medications on this site too.